European Hematology Association (EHA)-Haematology Society of Bangladesh (HSB) Hematology Tutorial

European Hematology Association (EHA)-Haematology Society of Bangladesh (HSB) Hematology Tutorial is organized by European Hematology Association (EHA) and will be held from Oct 03 - 04, 2025 at InterContinental Dhaka, Dhaka, Bangladesh.

Description:
EHA is joining the Haematology Society of Bangladesh (HSB) to organize the EHA-HSB Hematology Tutorial on Updates on Diagnosis and Management of Hematological Malignancies.

Goal of the Meeting:
This EHA-led Hematology Tutorial, focused on ‘Updates on Diagnosis and Management of Hematological Malignancies,’ is an educational meeting aimed at:

• Deepening the knowledge of hematology trainees and fellows in the diagnosis and management of lymphoid and myeloid malignancy
• Improving understanding of the recent innovation and new developments in the field
• Building the network with local and international experts in furthering hematology care and research in the region

Program:
Topics that will be covered are:

• Use of molecular technologies for diagnosis and monitoring of hematological malignancies
• Management of treatment resistant or relapsed acute myeloid leukemia
• Current management of relapsed & refractory Acute Lymphoblastic leukemia
• Management of treatment resistant CML
• Modern therapy for Multiple Myeloma and Chronic Lymphocytic Leukemia
• Updated management of Hodgkin Lymphoma
• Novel agents and autologous transplant in the management of treatment resistant T & B cell Lymphomas
• Updates on cellular therapy: Application of ASCT and CART cell therapy
• Hematological Malignancy Associated Coagulopathy

Learning Objectives:
After attending this tutorial, the participants will be able to:

• Gain enhanced ability to diagnose and manage the patient of Myeloid and Lymphoid malignancy including common forms of B cell and T/NK cell lymphoma; and Hodgkin lymphoma, acute and chronic leukemia both in the frontline and relapse setting with frontline updated strategy
• Benefit from the capability to choose between treatment options, novel agents, immunotherapy, or BMT appropriate to disease biology and patient profile